Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Koninklijke Philips NV — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.57, while Koninklijke Philips NV trades at $26.58 (market cap $26.19B). The key difference: Koninklijke Philips NV pays a 3.79% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Koninklijke Philips NV is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | PHG | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $32.91 |
52-Week Low | $116.45 | $24.54 |
Market Cap | — | $26.19B |
Enterprise Value | — | $32.46B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal. Recent dividends include $0.36 and $0.37 payouts in mid-2026. The ETF faces headwinds from rising Treasury yields and Federal Reserve uncertainty, as bond markets react to inflation and geopolitical tensions.
Outlook remains cautious due to interest rate sensitivity; opportunities exist for low-volatility Treasury exposure, but risks include further Fed hikes and competitive pressure from higher-yielding bond ETFs like Vanguard's offerings.
PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.
PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
